Freeman Daniel, Haselton Polly, Freeman Jason, Spanlang Bernhard, Kishore Sameer, Albery Emily, Denne Megan, Brown Poppy, Slater Mel, Nickless Alecia
Department of Psychiatry, University of Oxford, Oxford, UK; Oxford VR, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK.
Oxford VR, Oxford, UK.
Lancet Psychiatry. 2018 Aug;5(8):625-632. doi: 10.1016/S2215-0366(18)30226-8. Epub 2018 Jul 11.
Engaging, interactive, and automated virtual reality (VR) treatments might help solve the unmet needs of individuals with mental health disorders. We tested the efficacy of an automated cognitive intervention for fear of heights guided by an avatar virtual coach (animated using motion and voice capture of an actor) in VR and delivered with the latest consumer equipment.
We did a randomised trial of automated VR versus usual care. We recruited adults aged older than 18 years with a fear of heights by radio advertisements in Oxfordshire, UK. We diagnosed fear of heights if participants scored more than 29 on the Heights Interpretation Questionnaire (HIQ). We randomly allocated participants by computer in a 1:1 ratio to either automated VR delivered in roughly six 30-min sessions administered about two to three times a week over a 2-week period (intervention group) or to usual care (control group). Randomisation was stratified by severity of fear of heights. The research team, who were unaware of the random allocation, administered three fear-of-height assessments, at baseline (0 weeks), at the end of treatment (2 weeks), and at follow-up (4 weeks). The primary outcome measure was HIQ score (range 16-80, with higher scores indicating greater severity). This trial is registered with the ISRCTN registry, number ISRCTN11898283.
Between Nov 25, 2017, and Feb 27, 2018, 100 individuals were enrolled and underwent randomisation, of whom 49 were assigned to the VR treatment group and 51 to the control group. All participants completed the 4-week follow-up. The mean total treatment time in VR was 124·43 min (SD 34·23). Compared with participants in the control group, the VR treatment reduced fear of heights at the end of treatment (mean change score -24·5 [SD 13·1] in the VR group vs -1·2 [7·3] in the control group; adjusted difference -24·0, 95% CI -27·7 to -20·3; Cohen's d=2·0; p<0·0001). The benefit was maintained at follow-up (mean change score -25·1 [SD 13·9] in the VR group vs -1·5 [7·8] in the control group; adjusted difference -24·3, 95% CI -27·9 to -20·6; Cohen's d=2·0; p<0·0001). The number needed to treat to at least halve the fear of heights was 1·3. No adverse events were reported.
Psychological therapy delivered automatically by a VR coach can produce large clinical benefits. Evidence-based VR treatments have the potential to greatly increase treatment provision for mental health disorders.
Oxford VR, and the National Institute of Health Research Oxford Health Biomedical Research Centre.
引人入胜、具有交互性且自动化的虚拟现实(VR)治疗可能有助于满足心理健康障碍患者尚未得到满足的需求。我们测试了一种由虚拟化身教练(通过演员的动作和语音捕捉进行动画制作)在VR中引导并使用最新消费设备提供的针对恐高症的自动化认知干预的疗效。
我们进行了一项自动化VR与常规护理的随机试验。我们通过在英国牛津郡的电台广告招募了年龄超过18岁且患有恐高症的成年人。如果参与者在《高度解释问卷》(HIQ)上的得分超过29分,我们就诊断其患有恐高症。我们通过计算机以1:1的比例将参与者随机分配到在2周内每周大约进行两到三次、每次约30分钟、共约六个疗程的自动化VR治疗组(干预组)或常规护理组(对照组)。随机分组按恐高症的严重程度进行分层。对随机分配不知情的研究团队在基线(0周)、治疗结束时(2周)和随访时(4周)进行了三次恐高症评估。主要结局指标是HIQ得分(范围为16 - 80,得分越高表明严重程度越高)。该试验已在ISRCTN注册中心注册,注册号为ISRCTN11898283。
在2017年11月25日至2018年2月27日期间,100名个体被纳入并进行了随机分组,其中49人被分配到VR治疗组,51人被分配到对照组。所有参与者都完成了4周的随访。VR治疗的平均总治疗时间为124.43分钟(标准差34.23)。与对照组参与者相比,VR治疗在治疗结束时降低了恐高症程度(VR组的平均变化得分 -24.5 [标准差13.1],对照组为 -1.2 [7.3];调整后的差异为 -24.0,95%置信区间为 -27.7至 -20.3;Cohen's d = 2.0;p < 0.0001)。这种益处维持到了随访时(VR组的平均变化得分 -25.1 [标准差13.9],对照组为 -1.5 [7.8];调整后的差异为 -24.3,95%置信区间为 -27.9至 -20.6;Cohen's d = 2.0;p < 0.0001)。将恐高症至少减半所需的治疗人数为1.3。未报告不良事件。
由VR教练自动提供的心理治疗可产生显著的临床益处。基于证据的VR治疗有可能大幅增加对心理健康障碍的治疗服务。
牛津VR以及英国国家卫生研究院牛津健康生物医学研究中心。